The U.S. Justice Department has joined a Foreign Corrupt Practices Act investigation of Alexion Pharmaceuticals Inc. the company said in a securities filing. Alexion received a subpoena from the Securities and Exchange Commission in May and a request of voluntary production of documents from the Justice Department this month.
The previously disclosed SEC inquiry is related to the company’s grant-making activities and False Corrupt Practices Act compliance in various countries, concerning possible bribes of public officials or their agents. The company develops therapies for rare diseases. The nature of possible bribes is not yet known.